Bismuth subsalicylate

ApprovedSmall molecule

Biogen

Bismuth subsalicylate is one of 38 small molecule programs targeting Colitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColitisActive, not recruiting

MALT LymphomaActive, not recruiting

ColitisApproved

Active, not recruiting

MALT LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Colitis

#DrugCompanyPhaseTrials

Simponi

Johnson & Johnson

Approved

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Imuran

LLegacy Health System

Approved

1 5

Medrol

Pfizer

Phase 3

2 6

Dificlir

Merck & Co.

Phase 3

1 7

Remicade

OOrganon and Co

Phase 3

5 8

Stelara

Entyvio

3 10

Lialda

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diarrhea2 trials

Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Completed·CCenters for Disease Control and Prevention·N/A·NCT02047162·400 enrolled

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

Terminated·CCenters for Disease Control and Prevention·Phase 3·NCT03535272·482 enrolled

Helicobacter Pylori Infection1 trial

Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01742429·200 enrolled

MALT lymphoma1 trial

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002682·5 enrolled

Colitis1 trial

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Withdrawn·BBassett Healthcare·Phase 4·NCT03592082

Helicobacter Pylori Eradication1 trial

THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY

Completed·FFatih Sultan Mehmet Training and Research Hospital·Phase 4·NCT03757650·3 enrolled

2 more indications

Gastrointestinal1 trial

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Completed· Biogen logo

Biogen·Phase 1·NCT01915901·175 enrolled

Gut Microbiome1 trial

Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05930197·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bismuth subsalicylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bismuth subsalicylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bismuth subsalicylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Biogen

Bismuth subsalicylate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diarrhea2 trials

Helicobacter Pylori Infection1 trial

MALT lymphoma1 trial

Colitis1 trial

Helicobacter Pylori Eradication1 trial

Gastrointestinal1 trial

Gut Microbiome1 trial

References

Drug Info

Quick Facts

Related News